Availability of PRO data to providers for CTCAE rating improves the consistency of provider-based symptomatic adverse event detection in patients with cancer. PRO data supports reliable assessment of treatment-related toxicity, highlighting the value of integrating PRO data into clinical evaluations within cancer trials.
[Articles] Inter-rater reliability of CTCAE assessments with or without EORTC patient-reported outcome data in a mixed cancer population: a multinational, open-label, randomised controlled trial
The Lancet Oncology | | Lisa M Wintner, Monika Sztankay, Hikmat Abdel-Razeq, Renad Hamdan-Mansour, Giovanni Caocci, Guillaume Mouillet, Yuichiro Kikawa, Nobuhiro Shibata, Manjunath Nookala Krishnamurthy, Amit Joshi, Rahul Krishnatry, Aditi Jain, Helle Pappot, Duška Petranović, Antonela Trobentar, Heike Schmidt, Susann Schulze, Anastasia Tararykova, August Zabernigg, Johannes M Giesinger, Bernhard Holzner, EORTC Quality of Life Group
Topics: oncology